New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - ezetimibe 10mg;   - tablet - 10 mg - active: ezetimibe 10mg   excipient: croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate - ezetimibe sandoz administered with an hmg-coa reductase inhibitor (statin) or alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), and triglycerides (tg) and to increase high-density lipoprotein cholesterol (hdl-c) in adult and adolescent (10 to 17 years of age) patients with primary (heterozygous familial and non-familial) hypercholesterolaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - aripiprazole 10mg - tablet - 10 mg - active: aripiprazole 10mg excipient: hyprolose iron oxide red lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - aripiprazole 15mg - tablet - 15 mg - active: aripiprazole 15mg excipient: hyprolose iron oxide yellow lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - aripiprazole 20mg - tablet - 20 mg - active: aripiprazole 20mg excipient: hyprolose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - aripiprazole 30mg - tablet - 30 mg - active: aripiprazole 30mg excipient: hyprolose iron oxide red lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - aripiprazole 5mg - tablet - 5 mg - active: aripiprazole 5mg excipient: hyprolose indigo carmine aluminium lake lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - piperacillin monohydrate 4.198 g equivalent to piperacillin sodium 4.2531g and 4.0g piperacillin;  ;  ; tazobactam 0.5 g equivalent to tazobactam sodium 0.54733 g - powder for injection - 4 g/0.5 g - active: piperacillin monohydrate 4.198 g equivalent to piperacillin sodium 4.2531g and 4.0g piperacillin     tazobactam 0.5 g equivalent to tazobactam sodium 0.54733 g - indicated for the treatment of the following systemic and/or local bacterial infections in which susceptible organisms have been detected or are suspected: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated) 3. intra-abdominal infections 4. skin and skin structure infections 5. bacterial septicaemia 6. gynaecological infections 7. bacterial infections in neutropenic patients. full therapeutic doses of piptaz sandoz plus an aminoglycoside should be used. 8. bone and joint infections 9. polymicrobic infections: piptaz sandoz is indicated for polymicrobic infections including those where aerobic and anaerobic organisms are suspected (intra-abdominal, skin and skin structure, upper and lower respiratory tract, gynaecological). children under the age of 12 years in hospitalised children aged 2 to 12 years, piptaz sandoz is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - diclofenac sodium 25mg;   - enteric coated tablet - 25 mg - active: diclofenac sodium 25mg   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide iron oxide yellow lactose monohydrate magnesium stearate maize starch methacrylic acid copolymer microcrystalline cellulose purified talc sodium starch glycolate titanium dioxide triethyl citrate - treatment of: inflammatory and degenerative forms of rheumatism - rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and spondylarthritis, painful syndromes of the vertebral column, non-articular rheumatism; acute attacks of gout; post-traumatic and post-operative pain, inflammation, and swelling, e.g. following dental or orthopaedic surgery; painful and/or inflammatory conditions in gynaecology, e.g. primary dysmenorrhoea or adnexitis; as an adjuvant in severe painful inflammatory infections of the ear, nose, or throat, e.g. pharyngotonsillitis, otitis. in keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. fever alone is not an indication.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - diclofenac sodium 50mg;   - enteric coated tablet - 50 mg - active: diclofenac sodium 50mg   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide iron oxide yellow lactose monohydrate magnesium stearate maize starch methacrylic acid copolymer microcrystalline cellulose purified talc sodium starch glycolate titanium dioxide triethyl citrate - treatment of: inflammatory and degenerative forms of rheumatism - rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and spondylarthritis, painful syndromes of the vertebral column, non-articular rheumatism; acute attacks of gout; post-traumatic and post-operative pain, inflammation, and swelling, e.g. following dental or orthopaedic surgery; painful and/or inflammatory conditions in gynaecology, e.g. primary dysmenorrhoea or adnexitis; as an adjuvant in severe painful inflammatory infections of the ear, nose, or throat, e.g. pharyngotonsillitis, otitis. in keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. fever alone is not an indication.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - carvedilol 12.5mg;   - tablet - 12.5 mg - active: carvedilol 12.5mg   excipient: colloidal silicon dioxide crospovidone iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose povidone - carvedilol sandoz is indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).